Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Check the latest publications and updates here to make sure you don’t miss anything.
Clinical practice guidance in a modernised format that focuses on visual representation of recommendations for quick and easy reference by practicing clinicians.
To assist those using and/or evaluating the ESMO Guidelines, download the methodology here
Download the new version of our App with the latest Pocket Guidelines for oncology professionals
The essential content of the guidelines in condensed slide format in PDF or PowerPoint. Summary format including algorithms, figures and tables for your presentations.
The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics.
These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of cancer patients
The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically relevant topics and are produced by 20-40 key experts in the field.
This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline.
The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.
ESMO-MCBS scores are included in ESMO Clinical Practice Guidelines to help further guide treatment decisions.
A framework to rank genomic alterations as targets for cancer precision medicine.
ESCAT scores for genomic alterations with actionable drug matches are now being gradually integrated into ESMO tumour-focused Clinical Practice Guidelines.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
